Articles

In a phase 3 clinical trial, ruxolitinib (Jakafi) led to superior overall response rates and durable responses compared with best available therapy (ie, control group) in patients with steroid-dependent or steroid-refractory chronic graft-versus-host disease (GVHD), with acceptable safety, according to results presented at ASH 2020. Read More ›

The randomized phase 2 CAPTIVATE clinical trial showed that first-line therapy with ibrutinib (Imbruvica) and venetoclax (Venclexta) for a fixed duration (ie, 12 cycles) led to a 30-month progression-free survival (PFS) in more than 95% of patients with chronic lymphocytic leukemia (CLL) and undetectable minimal residual disease (MRD). Read More ›

In the cancer care setting, telehealth was perceived favorably by patients and providers, providing a new pathway for accessing treatment in the future. Read More ›

The pandemic shifted patients’ fears, highlighting the critical importance of physician trust and language used in recruitment. Read More ›

The delivery of care transformed rapidly as healthcare systems innovated to handle the COVID-19 pandemic. The overarching goals and principles of cancer care did not change, but there was a heightened recognition of the challenges faced by cancer patients. Read More ›

The latest quality-of-life research from the MONALEESA-7 trial supports a strong clinical benefit-to-risk ratio with ribociclib-based treatment in pre- and perimenopausal patients. Read More ›

In the future, telehealth may help overcome obstacles to healthcare access for underserved populations. Read More ›

Read More ›

Penn Medicine’s Abramson Cancer Center (ACC) is comprised of 6 hospitals and many facilities located in the tristate area of Pennsylvania, New Jersey, and Delaware. Read More ›